26 results
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
that will include health insurance, dental insurance, vision (VSP), short-term and long-term disability insurance. The Company retains the right
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
, and controls information; and any available human data or literature to support the use of the investigational product. Some long-term preclinical
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
, and controls information; and any available human data or literature to support the use of the investigational product. Some long-term preclinical
10-K
2023 FY
EX-97.1
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
by the restated financial statements:
Annual bonuses and other short- and long-term cash incentives.
Stock options.
Stock appreciation rights
10-K
2023 FY
EX-19.1
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
performance at the expense of the Company’s long-term objectives. Accordingly, transactions in put options, call options, or other derivative securities
10-K
zwagmn6p15lqv
16 Apr 24
Annual report
4:48pm
8-K
EX-99.1
wrwc 5hhpm4aag
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-1.1
0xxywyyg tynb
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
8blwcyheuvxar i3othh
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
4y4myq5h1ydpkoqh 12x
20 Feb 24
Prospectus supplement with pricing info
5:28pm